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Abstract
Background
Healthcare provider spontaneous reporting of suspected adverse events following immunisation (AEFI) is
central to monitoring post-licensure vaccine safety, but little is known about how healthcare professionals
recognise and report to surveillance systems. The aim of this study was explore the knowledge, experience and
attitudes of medical and nursing professionals towards detecting and reporting AEFI.
Methods
We conducted a qualitative study, using semi-structured, face to face interviews with 13 Paediatric Emergency
Department consultants from a tertiary paediatric hospital, 10 General Practitioners, 2 local council
immunisation and 4 General Practice nurses, recruited using purposive sampling in Adelaide, South Australia,
between December 2010 and September 2011. We identified emergent themes related to previous experience
of an AEFI in practice, awareness and experience of AEFI reporting, factors that would facilitate or impede
reporting and previous training in vaccine safety. Thematic analysis was used to analyse the data.
Results
AEFI reporting was infrequent across all groups, despite most participants having reviewed an AEFI. We
found confusion about how to report an AEFI and variability, according to the provider group, as to the type
of events that would constitute a reportable AEFI. Participants’ interpretation of a “serious” or “unexpected”
AEFI varied across the three groups. Common barriers to reporting included time constraints and
unsatisfactory reporting processes. Nurses were more likely to have received formal training in vaccine safety
and reporting than medical practitioners.
Conclusions
This study provides an overview of experience and beliefs of three healthcare professional groups in relation to
identifying and reporting AEFI. The qualitative assessment reveals differences in experience and awareness of
AEFI reporting across the three professional groups. Most participants appreciated the importance of their
role in AEFI surveillance and monitoring the ongoing safety of vaccines. Future initiatives to improve
education, such as increased training to health care providers, particularly, medical professionals, are required
and should be included in both undergraduate curricula and ongoing, professional development.
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Abstract
Background: Healthcare provider spontaneous reporting of suspected adverse events following immunisation
(AEFI) is central to monitoring post-licensure vaccine safety, but little is known about how healthcare professionals
recognise and report to surveillance systems. The aim of this study was explore the knowledge, experience and
attitudes of medical and nursing professionals towards detecting and reporting AEFI.
Methods: We conducted a qualitative study, using semi-structured, face to face interviews with 13 Paediatric
Emergency Department consultants from a tertiary paediatric hospital, 10 General Practitioners, 2 local council
immunisation and 4 General Practice nurses, recruited using purposive sampling in Adelaide, South Australia,
between December 2010 and September 2011. We identified emergent themes related to previous experience of
an AEFI in practice, awareness and experience of AEFI reporting, factors that would facilitate or impede reporting
and previous training in vaccine safety. Thematic analysis was used to analyse the data.
Results: AEFI reporting was infrequent across all groups, despite most participants having reviewed an AEFI. We
found confusion about how to report an AEFI and variability, according to the provider group, as to the type of
events that would constitute a reportable AEFI. Participants’ interpretation of a “serious” or “unexpected” AEFI varied
across the three groups. Common barriers to reporting included time constraints and unsatisfactory reporting
processes. Nurses were more likely to have received formal training in vaccine safety and reporting than medical
practitioners.
Conclusions: This study provides an overview of experience and beliefs of three healthcare professional groups in
relation to identifying and reporting AEFI. The qualitative assessment reveals differences in experience and
awareness of AEFI reporting across the three professional groups. Most participants appreciated the importance of
their role in AEFI surveillance and monitoring the ongoing safety of vaccines. Future initiatives to improve
education, such as increased training to health care providers, particularly, medical professionals, are required and
should be included in both undergraduate curricula and ongoing, professional development.
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Background
In Australia, the spontaneous reporting of adverse events
following immunisation (AEFI) is the primary mechanism
used for post-marketing passive surveillance (PMS) of
licensed vaccines. Passive AEFI surveillance is common
in many countries, worldwide [1-4]. The process relies
on immunisation providers, health professionals, and
consumers voluntarily submitting ad-hoc reports to jur-
isdictional public health and/or federal regulatory au-
thorities [5]. Vaccine manufactures are mandated to
report to the federal authority, the Therapeutic Goods Ad-
ministration (TGA), and in four of the eight Australian
states/territories, but not South Australia, health profes-
sionals are mandated by jurisdictional legislation to report
to the local public health authority. At the federal level up
until 2013, the Advisory Committee for Safety of Medi-
cines (ACSOM), a subcommittee of the TGA was respon-
sible for the ongoing evaluation of all drug and vaccine
safety. As of 2013, in response to recommendations for an
improved system of governance for vaccine safety moni-
toring [6], a new statutory Advisory Committee on the
Safety of Vaccines (ACSOV) has been established to
evaluate vaccine safety. Any medical events occurring
after vaccination, that are regarded as “serious” and/or
“unexpected” should be reported [7,8]. An established
causal association with vaccination is not a pre-requisite
for reporting [9].
Effective PMS is critical for a number of reasons. First,
for new vaccines, pre-licensure clinical trials are not
powered to detect rare adverse events that occur with a
frequency of less than 1 in 1,000, or with delayed onset,
and they are usually tested in homogeneous, healthy
study populations [3,10]. Thus, PMS aims to identify po-
tential safety signals which may require further investi-
gation not identified in pre-licensure trials and that may
become apparent outside the controlled conditions of
clinical trials. Secondly, for established vaccines, PMS
aims to monitor known adverse reactions and if the ob-
served rate exceeds the expected rate, further investiga-
tion is required. Finally, PMS should detect program
errors, such as incorrect vaccine administration or manu-
facture [11,12]. Hence, all licensed vaccines require specific
pharmacovigilance plans that incorporate post-licensure
passive surveillance and are “timely, efficient, sufficiently
large and in place for the life of the vaccine” [11]. An
example of the importance of voluntary reporting of
suspected AEFI was demonstrated by the withdrawal of
the Rotashield vaccine in the United States in 1999. Ten
months post-licensure and following 1.5 million doses ad-
ministered, 15 reported cases of intussusception, higher
than expected to occur, signalled the need for suspension
of its use and further evaluation of the vaccine [13].
Under-reporting is a known limitation of passive vac-
cine and adverse drug reaction (ADR) surveillance
systems [12,14]. In Australia this is demonstrated by the
marked variation of AEFI reporting rates across jurisdic-
tions for the same vaccines [15,16]. The importance of
and need for timely healthcare provider reporting of
AEFI as they occur was highlighted by a recent Austra-
lian experience of a vaccine safety signal. On the 23rd
April 2010, a seasonal trivalent influenza vaccine (STIV)
for children aged less than 5 years was suspended na-
tionally for three months due to an increased incidence
of fever and febrile convulsions, [17] associated with the
vaccine brand, Fluvax (CSL). In an analysis of AEFI re-
ports submitted to the South Australian Department of
Health in the first six months in 2010, the majority
(71%) of influenza AEFI reports submitted by healthcare
providers were received after the STIV program was
suspended [18]. Subsequent reviews of AEFI surveil-
lance in Australia following the STIV suspension have
suggested that under-reporting and delayed reporting of
febrile convulsions, contributed to delays in signal de-
tection [6,19].
Healthcare professional AEFI reporting is an under-
researched area, with only four studies conducted else-
where, published to date [20-22]. All four studies
employed quantitative methods to either measure aware-
ness of surveillance, reasons for reporting or to compare
actual AEFI reports by health professionals. The first ex-
amined Canadian family physicians’ awareness of vaccine
safety monitoring systems and reporting frequency for
vaccine associated adverse events [20]. Less than half of
the study respondents were aware of a monitoring sys-
tem for AEFI, only one third knew of reporting criteria
and only one in four had received vaccine adverse event
education during medical training. The primary reason
for not reporting was that an AEFI was never observed,
the respondents did not know reporting was expected,
the event did not seem serious enough or respondents
were not aware of reporting procedures. Ranganathan
et al. (2003) examined AEFI reports of Meningococcal
serogroup C Conjugate (Men C) vaccine submitted to
the Yellow Card Scheme (United Kingdom) by hospital
doctors, General Practitioners (GPs) and nurses [22].
This study found nurses reported AEFI more frequently
compared with GPs and hospital doctors and that com-
pleteness of the reports varied across the professional
group. The third study of health professional AEFI
reporting conducted in the United States included physi-
cians, pharmacists, and nurses [21] and examined the
frequency of reporting to the Vaccine Adverse Event
Reporting System (VAERS), beliefs and awareness of
AEFI reporting, barriers to reporting and strategies to
increase reporting rates. Of all respondents, 71% had
never reported an AEFI, with 17% indicating they were
not aware of how to report. The study demonstrated sig-
nificant differences in having ever reported an AEFI by
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health professional type. Barriers to reporting included
unclear definitions of a reportable AEFI, time pressures
in completing a report, and confusion in whose respon-
sibility it was to report. Reporting was associated with
being alerted to look for specific events, discounting
other explanations for the adverse event; observing the
same AEFI repeatedly and whether the events occurred
in vulnerable patient groups such as pregnant women,
infants or patients aged ≥65 years. The fourth study is
the most recent conducted to date and included family
physicians, physician assistants, nurse practitioners, prac-
tice nurses and nurses working in paediatrics, family medi-
cine and internal medicine [23]. The survey assessed
demographics and professional characteristics and know-
ledge and attitudes toward identifying and reporting an
AEFI to the Vaccine Adverse Event Reporting System
(VAERS) in the United States. Although nearly three quar-
ters of study participants were familiar with VAERS, only
14% were “very” or “extremely” familiar with the paper
reporting procedure and approximately one third were
not familiar when it was required to report an AEFI.
Approximately 40% of all study participants had identified
at least one AEFI, with only 18% indicating they had
reported to VAERS. Respondents indicated they would re-
port serious AEFI regardless of whether they were known
(73%) or unknown (62%) to be associated with immunisa-
tion. Those who indicated that they were not familiar with
submitting a paper report to VAERS were more likely
not to report than those who were familiar with the
process. Similarly, respondents who were not at all fa-
miliar with reporting criteria to VAERS tended not to
report compared with those who were familiar with the
requirements.
Studies of adverse drug reaction (ADR) reporting by
health professionals have identified several factors that
are common to under-reporting of AEFI. Ignorance of
reportable events, lack of awareness of a reporting sys-
tem, insecurity regarding causation (not possible to as-
certain whether the drug caused the reaction) and lack
of time are common reasons associated with lack of
reporting [14,24-28]. Other factors not demonstrated in
previous AEFI studies that have been associated with
under-reporting of ADR include fear of litigation; indiffer-
ence; lack of financial incentives to report and a belief that
only safe drugs are released into the market [24,25]. Some
parallels exist in adverse medical incident reporting stud-
ies. These studies reveal parallel differences in reporting
behaviour between medical specialties where nurses are
more likely to report to internal incident reporting sys-
tems than doctors and ‘the fear of blame’ as a common
barrier to reporting by doctors [29-31].
Consumer perceptions and experience of health pro-
fessional ADR reporting have demonstrated concern
that health professionals’ lack of clarity in recognising
adverse medicine events prevents reporting of potential
adverse events [32,33]. Two recommendations arising
from a meeting of the Consumers Health Forum of
Australia (CHF) in June 2011 were to improve and en-
courage adverse event reporting processes through train-
ing and education for health professionals [34]. These
recommendations are echoed in a national review of
Australian AEFI surveillance following the 2010 STIV
safety signal to increase both consumer and health pro-
fessional awareness of AEFI reporting and to improve
communication and notification of AEFI between juris-
dictional and federal health authorities [6].
It is likely that differences in healthcare provider AEFI
knowledge and practice of reporting results in incon-
sistent adverse event data collection and, ultimately,
inaccurate measurement of the incidence of vaccine ad-
verse events, by delaying or missing important vaccine
safety concerns [35]. Since spontaneous reporting is
central to passive vaccine PMS and given that health
professionals provide the majority of AEFI reports to
surveillance systems [36], it is important to understand
not only the factors such as awareness of and frequency
of reporting, but also how health professionals identify/
conceptualise a reportable AEFI. This paper presents re-
sults of a qualitative study that aimed to determine how




Following a review of key findings from existing litera-
ture on AEFI and ADR reporting as described above and
information obtained from a study of parent AEFI re-
porters we had previously conducted [37], we chose to
adopt in-depth qualitative interviews for the study de-
sign as it was most suited to our research questions:
What are the experiences, awareness and knowledge of
healthcare providers in AEFI reporting and how do
healthcare providers conceptualise a reportable AEFI?
These questions and the associated study design are
consistent with a social constructionist paradigm in
qualitative research, enabling the interviewer to make
meaning of each participant’s “world”, their individual
perspectives and meanings in a context that is shaped by
their organisational environment and broader social
structures [38].
We chose to conduct individual, face to face interviews
as appropriate to examine each participant’s specific ex-
perience and understandings of AEFI and because it was
most suited to participants’ work schedules. The inter-
views were conducted with the General Practioners (GPs)
and Paediatric Emergency Department (PED) consul-
tants, between December 2010 and February 2011.
Based on preliminary analysis of the interview data, it
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was recognised that nurses also played an important
role in AEFI reporting, and a further six interviews were
conducted with two local council immunisation and
four general practice nurses in September 2011.
Recruitment
We recruited twenty-nine healthcare professionals from
an Emergency Department of a tertiary, paediatric hos-
pital, GP clinics, and local council immunisation clinics
in Adelaide, capital city of South Australia (population
1.6 million). Characteristics of participants are presented
in Table 1. Purposive sampling was used to identify par-
ticipants for the study [39]. The participants recruited in
each category (see Table 1) represented a range of health
professionals who were in a position to detect, manage
and/or report an AEFI. The PED consultants were
recruited via the Emergency Department with initial in-
formation about the study communicated to participants
via the head of Emergency. All consultants except one
agreed to participate. We used three strategies to recruit
the GPs including contacting potential participants via
professional (university research academics and clinical)
contacts of the authors, advertising via an electronic distri-
bution mail list of the local branch of the Royal Australian
College of General Practitioners and finally via electronic
communication within an academic organisation involved
in training general practitioners. The study nurses were
recruited via contacts of the authors, the general practice
clinics involved in the study, and via the local Department
of Health Immunisation Section.
Topic Guide
The semi-structured, open-ended interviews were
conducted using a topic guide (see Table 2). The original
interview schedule was developed from a review of key
findings of literature surrounding AEFI and ADR
reporting as described earlier. Each interview sought to
explore participants’ knowledge and experience of
detecting, managing and reporting an AEFI; factors that
would facilitate or impede AEFI reporting; understand-
ing of AEFI surveillance and previous training in vaccine
safety. All interviews were conducted at participants’
workplace, ranging from 25 to 65 minutes.
Ethical considerations
Participation was voluntary and signed, informed con-
sent was obtained before conducting the interviews. The
study was approved by the University of Adelaide and
Children Youth and Women’s Health Service (CYWHS)
Human Research Ethics Committees. This study ad-
hered to the qualitative research review guidelines
(RATS) [40].
Analysis
Each interview was audio-taped and data transcribed
verbatim by AP. Thematic analysis was used to structure
analysis of the transcripts [41] with NVivo, version 9
(QSR International, UK). Initially, open coding of inter-
view data was undertaken. These codes were generated
inductively from participants’ descriptions of their expe-
riences in responding to and reporting an AEFI, and
awareness of vaccine safety surveillance. Following initial
coding of transcripts, preliminary themes that captured
information relevant to the research questions were gen-
erated. This process involved identifying patterns in the
data: recurring ideas, perspectives and descriptions that
depicted each participant’s context and perspective. The
final analysis for this study focussed on key themes, nar-
ratives, and professional histories emerging from the in-
terviews. Data concordance was verified by AP and
ABM, a trained qualitative researcher with extensive ex-
perience in medical and public health qualitative re-
search. Key themes were discussed with the research
team that included two clinicians with expertise in vac-
cine safety and surveillance (HM and MG) at regular
team meetings. We achieved topical saturation as similar
themes emerged from various participants from each
professional group after preliminary analysis of initial in-
terviews. Quotes that best illustrate important represen-
tation of participants’ views and experiences identified
through our iterative process of review and discussion
are presented in the following section.
Results
Previous experience of an AEFI and reporting
Most participants (27/29) reported seeing or being in-
volved in the care of children or adults with a suspected
AEFI, in their current or previous workplace. The cases
included children presenting with suspected hypotonic
hypo-responsive events, anaphylaxis, febrile convulsion,
non-febrile convulsions, extensive limb swelling, high fe-
vers and skin rashes (reported as allergic events). Al-
though participants described experience of at least one
AEFI throughout their career, most stated they were
Table 1 Study participants
Professional group Female Male Age range (years) Mean number of years worked in professional group
Nurse 6 0 31-53 19
Paediatric Emergency Department specialist 6 7 35-57 15
General Practitioner 8 2 40-57 21
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“rare” or “not that common”, and occurred “years” prior
to the interview. The most recent events recalled were
febrile convulsions following STIV vaccination in 2010
and a “severe local swelling” in the week prior to the
study interview.
“I haven’t had a lot of adverse reactions at all. They’re
quite rare actually. If you think of the number of kids we
vaccinate. I’ve had lots of local reactions but I don’t
recall off the top of my head any significant.” GP 9
“We’d still be seeing the reactions rather than but no,
not very common at all. Even less since we’ve used the
acellular vaccine, even less.” GP 7
Of all participants, 19/29, (7 GPs, 5 nurses and 5 PED
consultants), indicated they had reported an AEFI to a
surveillance system at some point in their career, either
in Australia or overseas. Only two participants stated
they had reported more than once, despite the fact that
most had worked for many years in the health system (a
mean of 18 years for all three groups). When asked to
recall when they had reported, a common response was
in the distant past, with some as far back as “fifteen or
twenty years ago.”
“That one with the measles I would have reported. I
think there was a couple of others too but it’s going
back a long way.” GP 7
Awareness of reporting
All nurses were familiar with paper and telephone
reporting procedures to the local Department of Health
and also described their workplace reporting processes,
such as having the report forms on hand and/or an
existing protocol for reporting adverse events (Table 3).
Six of the thirteen PED consultants (46%) stated they
were not aware of a system for reporting or how to re-
port an AEFI.
Table 2 Interview topic guide
Theme Guiding question
Experience of an AEFI 1. Could you tell me about an AEFI you have seen during the course of your work?
2. How often have you seen an AEFI in this workplace or during your career?
3. How did you respond to the AEFI?
4. How did the event turn out?
Reporting an AEFI 1. Have you ever reported an AEFI? Why?
2. How have you reported?
3. Was it an easy/difficult process? Could you explain?
4. If you talked to an authority about the event what was the response from the person?
5. If you needed to report an AEFI today how would you do it?
6. What do you think are the main factors that would lead you to report an AEFI?
7. Why would you report an AEFI?
8. What would you not report as an AEFI?
9. What would be your preferred format for reporting? Why?
Workplace 1. Can you tell me about whether AEFI are discussed with your colleagues?
2. Could you describe any policy/protocol for reporting an AEFI in your workplace?
Surveillance 1. Could you describe your understanding of how vaccines are monitored for safety after they are released to the public?
2. Who do you think should be responsible for monitoring vaccine safety in Australia?
3. How do you access communication regarding vaccine safety issues?
4. Is there sufficient information available to you from surveillance authorities or other sources? Explain.
5. In your opinion, who should be responsible for monitoring the ongoing safety of vaccines?
6. What do you think happens after an AEFI report is made?
7. What is your impression of how safety is monitored?
Training 1. Could you tell me about any training you have had in vaccine safety either during your career or as a student?
2. How do you update your knowledge in vaccine safety?
3. What would be an ideal way to update or provide training?
4. Do you think doctors and nurses have sufficient training and knowledge in current vaccine safety issues? Why?
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“I would probably have to ask my colleagues how to do
it.” ED 4
“I’d have to ask one of the other consultants what the
procedure was, because I don’t currently know.” ED 9
Two GPs were not aware of how to make a report,
even though one stated having reported previously. The
second GP had previously diagnosed an AEFI which
would have been reported, had she known of a reporting
system.
“I found it difficult to try and find out where I was
meant to report and then due to competing demands
didn’t seek further information.” GP 5
For those who indicated awareness, reporting was
thought to occur generally either via the national adverse
drug reporting system or the local Department of Health.
Few participants indicated awareness of both national and
local reporting systems. We found participants were gen-
erally confused about the various reporting options and
unaware that reports could be notified via phone, postal,
fax, electronic or online submission.
“It would be helpful if the practice nurses could report
on my behalf.” GP 10
“It would be nice to have a number, a telephone
number with who to go to. That’s the sort of thing we
probably need with adverse events to vaccines.” GP 6
When describing awareness of workplace policies, par-
ticipants were also prompted to describe whether AEFIs
were discussed during the course of their work. If an
AEFI was discussed in the various workplace settings, it
Table 3 Participants’ awareness of AEFI reporting protocol or policy in their work setting
Nurses General practitioners ED consultants
If we see an adverse event, then we do report.
We have the forms for reporting. (General
Practice nurse)
I think I would say that you know the majority
that would be 99%, is done by our nurse and
would probably only get reported from the
nurse
I’d have to double-check. I’d have to ask a
colleague
I would say there’s one in the policy manual.
(General Practice nurse)
No I don’t know that there is one here actually. We can just click on forms, adverse events
reporting form and just print it out, so that’s
what we do.
The forms are in our filing cabinet. But I know
you can get it from SAICU and I know it’s on
their website. We’re actually in the process of
doing a procedure, protocol. (General Practice
nurse)
I would say there wouldn’t be anything
completely formal that we’ve ever discussed at
a meeting or anything. I don’t think there’s
ever been a formal policy. No.
Not answered
Not actually in writing but because I’m the only
one here generally, anything that’s out of the
normal goes past me anyway. We always keep a
copy of them (the adverse event reporting form)
at the clinics. (Council immunisation nurse)
Not that I’m aware of. There may be, but not
sure.
I don’t really know because I’ve never had to do
it because obviously it’s quite rare.
I do the reporting and advise the doctors that
I’ve done that as well. If we do any written
documentation it’s always scanned into the
notes too. (General Practice nurse)
No actually we don’t as far as I know have a
policy. Probably we should, but no we don’t.
I would have to look at information on our
intranet that has information about reporting
adverse reactions to vaccines and remind myself
how to do it.
It is in our standard operation procedure that we
do have that, if an adverse event occurred, it just
says fill in a form. (Council immunisation nurse).
Well our practice nurse looks after all these
things and she would report.
I remember looking up a number probably from
the Immunisation Handbook.
No not specifically. There hasn’t been a
designated discussion about what we do
about these things when they occur.
I don’t think so. I’m not familiar with a
documented protocol as such.
There’s those blue forms. I’d have to ask one of the other consultants what
the procedure was, because I don’t currently
know.
Not formal, but we know to report to ADRAC. We’ve got it on our web on our intranet there’s
links to it. The numbers there or you make the
notification or you just fill it in and send it off.
I’d have to see what the protocol was, but we
haven’t had one for so long
Reporting would not be protocolised.
We’ve got the blue forms. We fill in the blue
forms and send them off.
No, there is no protocol
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would usually occur informally with colleagues if a
patient presented with symptoms that were unusual or
serious. For example, in the hospital setting, around the
time of the influenza safety signal in 2010, the ED con-
sultants recalled informal discussions with colleagues of
febrile convulsion cases presenting to the ED. The
nurses would discuss cases that were “out of the norm”.
“We do discuss it between us quite a lot if you get
something quite a bit different. You know such and
such happened have you had that happen with yours
or are you aware of that being anything? So we do
usually discuss it amongst ourselves.” GP 6
“We tend to talk about things that happen. If it was
something serious I think generally we would discuss
those things.” GP 7
Recognition of a reportable AEFI
Participants were asked to describe the types of events
they would consider necessary to report. All stated that a
reportable AEFI was an event characterised as “serious”
and/or “unexpected”. Reactions were generally considered
serious if they were life-threatening (such as anaphylaxis);
clinically significant or severe (for example, convulsions);
and/or relevant to the patient’s future vaccinations,
because of the potential impact on future vaccination
decisions.
“I’ve never seen an anaphylaxis. I’ve never seen a
hypotonic reaction. I’ve never seen anything I would
classify as serious. Ever. I’ve never seen an AEFI that
I’ve had to report.” GP 3
“Most of the cases that present actually aren’t
significant events. So, that would be the usual fevers
following vaccinations or localised reactions. Few
actually meeting the criteria for being significant. I’ve
not seen anyone with an anaphylaxis.” ED 9
Two underlying interpretations were evident when
participants described an “unexpected” AEFI. In the first
instance, “unexpected” referred to an event that was
rare, but with a known (but low) probability of occur-
ring, such as anaphylaxis. These were regarded as unex-
pected because they were more severe and less common
than the “normal” vaccine reactions.
“Beyond the reasonable in terms of you know what you
would expect. It’s obviously more severe.” Nurse 3
When compared by professional group, all GPs and
nurses would report this type of unexpected AEFI, (se-
vere or rare, but previously recognised), whereas only
half of the PED consultants explicitly stated or implied
this. Discussion regarding febrile convulsions illustrated
a difference in interpretation of “unexpected” across the
groups. Most PED consultants stated that they had man-
aged children who had experienced febrile convulsions
in relation to influenza vaccination in 2010; however,
only three could recall reporting this as an AEFI. When
discussing the 2010 safety signal and opinions of why fe-
brile convulsions were not reported, several reasoned
that they are a known AEFI, that the children had expe-
rienced relatively minor convulsions, and that only
prolonged convulsions that were “clinically significant”
should be reported.
“I guess you know we saw a number of children not
long after the vaccine was released with febrile,
apparent febrile reactions to the vaccine who didn’t
appear to be particularly otherwise unwell. I guess
febrile reactions to vaccines are relatively common,
that we weren’t particularly perturbed about it at all
until there were reports of children becoming quite
unwell and having prolonged convulsions and there is
significant morbidity associated with those,
particularly interstate. I’m not sure whether there were
terribly many in Adelaide.” ED5
The PED consultants tended to describe as reportable
only those events that were very severe or life-
threatening, often referred to as “clinically significant” or
“dangerous.”
“I think it has to be a very significant event… where
it’s well above the normal thing and potentially quite
dangerous.” ED 6
The second meaning attributed to “unexpected,” was a
reaction that was not known to occur following vaccin-
ation. This type of AEFI would be reported because
there was no established scientific evidence available that
connected it to a vaccination.
“If a child came back the next day or a week later and
had an illness or an event that I couldn’t in my mind
relate necessarily to the vaccine then yes I would.”
GP3
In addition to serious and unexpected reactions, some
participants considered all adverse events occurring
following newly released vaccines should be reported.
Three participants stated all reactions, regardless of se-
verity, should be reported.
“Well I guess theoretically any reaction to a vaccine
should be notified, even if it’s a minor reaction. The flu
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vaccine was a good case in that although we saw the
children as having relatively minor febrile reactions to
the vaccine there was obviously children who were
having more severe end of the spectrum reactions
associated with fever, so it’s a good illustration that
probably any reaction to a vaccine should probably be
notified.” ED 1
“I think any adverse event no matter how little or
large needs to be reported.” Nurse 2
Barriers to reporting
When discussing vaccine safety surveillance, most partici-
pants stated the critical role of healthcare providers in
reporting AEFI but also recognised the limitation of passive
surveillance of relying on healthcare providers to report.
“If you don’t have reports you don’t know how it’s
going out there in the arena, do you?” Nurse 6
“Well I think everyone involved in administering
vaccines which includes GPs and nurses and anybody
seeing people. So, it’s really, all of us have to play a
role.” GP 4
“It seems to be more clinical adverse reactions are
heavily dependent on the clinician reporting them.”
ED 10
“There’s a lot of assumptions made. We’re assuming
someone’s going to tell us and then we’re assuming
that we’re going to notify someone else when we find
out.” GP 9
Although reporting by health professionals and the
public was understood as key to monitoring AEFI, two
participants did not believe they shared responsibility for
AEFI surveillance.
“Not me. I don’t know. There’s probably some
immunisation body.
The only way you’re going to know that there’s some
problem with a vaccine is if people are going to report
significant events post –vaccine. And then someone
else can sort it out.” ED3
“I think it should be a government department because
it’s a public health issue.” GP5
The amount of information required in completing a
report, time constraints, competing workplace priorities
in the workplace and dissatisfaction with reporting
methods were identified as barriers to reporting by the
GPs and PED consultants. By contrast, the nurses did
not describe any of these barriers.
“Busy clinicians really don’t have time to sit down and
fill out several pages of report form.” ED 1
“The reporting system is too difficult. The only way I
want to report anything is automatically through my
software.” GP4
Preferred format for reporting
Participants’ preferences for a preferred format for
reporting an AEFI varied across the three professional
groups, and covered the current options for paper, phone,
fax and electronic reporting. The nurses preferred either
the phone or paper reporting, the GPs, phone or web-
based reporting and the PED consultants varied in their
opinions, stating paper/fax, phone and electronic formats.
The phone was often stated as a convenient method for
communicating and receiving immediate feedback/response
with an immunisation professional. Paper reporting was be-
lieved useful to have a record or “trail” of communication
with the local Department of Health and for the purpose
of having patients’ events recorded with their medical
history.
“I prefer phone because I can ask questions for myself,
as for if there was any correlation. So I’m reporting the
incident but also following-up the information for
myself or for the patient.” Nurse 3
When discussing ideal electronic formats, GPs and
PED consultants suggested creating systems that were
linked to their workplace systems/practice management
software and allowed for automatic submission.
“With electronic, particularly if there is a system built
into your database using emergency as an example, if
there is a reporting form built into the system so that
it’s prepopulated with demographic data and all you
need to do is click some boxes, the form would be sent
in automatically.” ED 5
Training
All nurses had received some formal training in vaccine
safety and AEFI reporting, such as Division of General
Practice, Department of Health workshops, or post-
graduate university training for immunisation providers.
Most of the GPs and PED consultants could not recall
specific training either pre- or post-graduation. All GPs
and most PED consultants believed that, in general, doc-
tors’ pre-service education in vaccine safety and adverse
event reporting was inadequate.
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“I can’t remember having any specific training on
immunisations or reporting and adverse reactions. It’s
just assumed that we have obtained that knowledge
somewhere rather than actually having a specific
study or certification in vaccine.” ED 8
“I would have to say I don’t think I had any training
as a student at all. Or at least can’t recall it. I can’t
remember hearing anything about vaccinations in
medical school apart from sick people with COPD
need vaccinations but nothing about the vaccines or
safety.” GP 5
All participants supported strategies for updating know-
ledge via the continuing medical education programs of
their relevant professional accreditation organisations.
Discussion
This is the first qualitative study, to our knowledge,
that explores healthcare provider AEFI reporting
awareness, practices and attitudes. We found reporting
was infrequent across the three groups interviewed
and conflicting views between groups as to what events
would constitute an AEFI. Potential reasons for this
could be that an AEFI occurs infrequently; that an
AEFI is not recognised as such; and/or that an AEFI is
recognised, but not reported. Our results show events
which were either completely unexpected (that are not
known to occur following vaccination), or which might
represent an increase in expected reactions were less
likely to be reported.
This study has shown that the requirement for all “ser-
ious” events to be reported to authorities, regardless of
whether they were causally related to the vaccination,
was interpreted differently amongst participants and by
professional group. All participants would report the
most severe events, often termed “life-threatening,” or
“dangerous.” However, we found from the PED consult-
ant interviews that, on the whole, they would only report
events that were perceived as “life threatening.” Com-
pared with the nurses and GPs, they were less likely to
report other events that were not as severe and those
that are a known AEFI. The under-reporting of febrile
convulsions following STIV in April 2010, could possibly
be an illustrative example. Based on these interviews, we
could reason that the PED consultants did not report fe-
brile convulsions because this is a known complication
of immunisation associated with fever. Taken together
with the belief that most of the children they treated had
experienced minor, (or not clinically significant) convul-
sions illustrates their differing interpretation of “serious”
compared with GPs and nurses. Possibly, working in an
environment in which one regularly sees serious and
life-threatening presentations, compared with other
settings, such as an immunisation clinic or family physi-
cian’s workplace, increases a hospital emergency doctor’s
threshold for the definition of “severe” or “serious” and,
therefore, what would be reported. Viewed in this light,
under-reporting can be explained partly by the varied in-
terpretation of what constitutes an AEFI.
The context of the workplace setting in this study is
important to consider in relation to understanding fac-
tors that might influence a health professional’s decision
to report an AEFI. We did not seek information from
each work setting involved about whether in fact there
was an established policy or protocol for reporting.
However, from the interviews we conducted, it was ap-
parent that reporting was an established norm for im-
munisation nurses in local council clinics, as a council
nurse’s core work is providing immunisations to the
public. Having report forms at hand and documented
protocols for AEFI reporting facilitated reporting in such
settings. We suggest there are three possible explana-
tions for the variations in awareness of participants from
the general practice and hospital settings (Table 3). First,
it may be that there was no current policy in place. Sec-
ond, if a policy existed, it had not been introduced or
established effectively within the workplace. For ex-
ample, in the hospital setting, the ED consultants did
have access to the local Department of Health reporting
form via the internal intranet; however, few indicated
awareness of it during interviews. This would suggest a
need to ensure staff are informed and updated about
accessing the reporting link. Given that the study oc-
curred less than 12 months after the safety signal associ-
ated with the seasonal influenza vaccine and subsequent
relay of public health alerts to hospitals and primary
healthcare settings regarding the occurrence of febrile
convulsions and need to report, it was surprising that
there were such low levels of awareness. A third explan-
ation for low levels of awareness amongst the GPs and
ED consultants could be that reporting was not seen as
a prime function of medical staff and might be delegated
to nursing or administrative staff. Apart from one GP
who indicated that the nurse at his practice would be re-
sponsible for reporting as part of her role in immunising
patients, we found no evidence of delegated reporting
amongst the GPs. In the ED setting, delegating the
reporting to a registrar who was undertaking an ED
rotation was described by some consultants and
hence could explain their unfamiliarity with the ac-
tual processes of reporting, regardless of whether it
was to local or national surveillance authorities. In
this context one could speculate that reporting was
not seen as a primary function of the clinician, but
rather an administrative function to be performed by
non-medical staff or, as in the ED setting, junior
medical staff.
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Despite the limitations of passive surveillance, it is not
likely to be replaced by alternate methods of surveillance
that do not rely on healthcare professionals’ awareness
or readiness to report, such as data linkage [42-44]. Pas-
sive surveillance should monitor vaccine safety and detect
safety signals in real time or near-real time. Alternate
methods of surveillance such as data linkage or sentinel
surveillance are usually used to detect known events and
to test hypotheses for associations between a vaccine and
an AEFI [45] but are limited by timeliness of reporting.
Thus, there is an ongoing need for robust passive AEFI
reporting systems. From this study it is clear that, even if
an AEFI is recognised, there are significant barriers to
reporting by health care providers. These barriers are con-
sistent with factors identified in previous studies of AEFI
and ADR reporting [20,21,24] and include a lack of aware-
ness or confusion about reporting systems, a lack of time
to report and differing perceptions of a reportable AEFI.
Unlike other studies, we did not find evidence about
fear of litigation, or that vaccine adverse events are not
reported because of inherent trust that licensed vaccines
are all safe [24].
Few participants in this study were aware of both local
and national reporting processes. Future research should
explore whether a single pathway for AEFI reporting
may be preferred by healthcare providers, rather than
the existing system which provides a choice between
reporting to the local Department of Health within each
Australian jurisdiction or the national body (TGA). We
also found differing preferences for the varied methods of
reporting. In addition to these barriers, under-reporting
may in part be attributed to the administration of less
reactogenic vaccines in more recent years that has resulted
in lower occurrence of some reactions. This would result
in less awareness of reporting, as practitioners are less
likely to be familiar with a system if they do not need to
use it. However, this would not explain the differences in
awareness across the three professional groups, as nurses
were more familiar with both reporting processes and spe-
cific workplace protocols for reporting.
We found the nurses were more likely than the doctors
to have received formal training in vaccine safety surveil-
lance, which generally occurred as professional develop-
ment training. This finding is consistent with previous
published studies that reported low levels of vaccine safety
education during medical training in Europe and Canada
[20,46] and an unpublished, cross-sectional survey of 452
GPs, GP nurses, midwives, paediatric and community
nurses, conducted in Sydney, Australia [47]. Our study
confirms a need to provide adequate education across
healthcare providers’ training, both pre- and in-service,
which has been recognised internationally [46,48]. Adverse
event reporting should be incorporated in continuing
medical education programs.
The strength of this study lies in its qualitative ap-
proach. This format allowed participants to provide de-
tailed accounts of their experiences and understanding
of AEFI and reporting system. We were also able to
sample participants from different work settings and
professions. However, there were some limitations that
may affect the generalisability of our findings beyond
this study. Firstly, our participants all came from the one
jurisdiction, and their responses may have been shaped
by the organisational context for reporting of AEFI in
that jurisdiction. Second, we acknowledge that partici-
pants in this study self-selected to participate and may
provide an element of responder bias, since more moti-
vated individuals or those with an interest in immunisa-
tion may have participated. However, we expected that
responder bias would have been associated with greater
familiarity with AEFIs and reporting systems than was
evidenced in our study. Third, most participants had
completed undergraduate training decades previously
and this may have influenced their recall of adverse
event training.
Our findings support the recommendations of the two
reviews into AEFI surveillance in Australia, which were
initiated because of the occurrence and delayed detec-
tion of febrile convulsions post STIV in 2010. Both re-
views highlighted deficiencies in healthcare provider
reporting [6,19] and recommend a need to improve
AEFI detection and reporting by introducing strategies
aimed at increasing awareness of national reporting and
strengthening communication within the surveillance
system. Future research that would inform strategies to
improve AEFI reporting should aim to include the per-
spectives of workplace managers and surveillance au-
thorities as key informants.
Conclusion
Although the majority of participants had observed an
AEFI in clinical practice and understood the importance of
their role in AEFI reporting for post-marketing safety sur-
veillance, we found reporting was infrequent. Reporting
was related to the perceived interpretation of a reportable
AEFI. The current guideline of reporting “serious” and “un-
expected” events was interpreted differently in the three
work settings and this would suggest there needs to be
clearer definition and guidelines about reportable adverse
events. Barriers to reporting included lack of time and
knowledge of reporting processes. To test the magnitude
of these factors, further research should be conducted
among a larger representative group of healthcare profes-
sionals across Australia.
The participants’ recall of training in vaccine safety
suggests that there is a need to increase education and train-
ing in vaccine and drug adverse events and current
reporting methods, at both undergraduate and postgraduate
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levels, particularly for medical professionals. Specific strat-
egies for updating knowledge should be implemented via
the professional relevant accreditation bodies and continu-
ing medical education programs.
The surveillance system and its methods for reporting
should be easy to access, widely promoted and “user
friendly” to both health professionals and consumers
with formats for reporting designed so that the system
is accessed effectively in different work settings. The
limitation of any passive surveillance system is the sub-
mission of reports and the barriers identified in this
study should be addressed as the Australian system is
strengthened.
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